Skip to main content

Advertisement

Fig. 3 | Arthritis Research & Therapy

Fig. 3

From: Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies

Fig. 3

Shift analysis of enthesitis count from baseline to weeks 24, 52, and 104. A, B, and C represents EC = 1, 2, and 3–6 at baseline, respectively. EC 3–6 group includes patients with baseline EC 3, 4, 5, or 6. Shift analysis on resolution of EC from baseline to week 24/52/104 is categorized based on the three criteria of resolution: FR (EC = 0), stable (0 < EC ≤ baseline EC), and worse (> baseline EC). EC, enthesitis count; FR, full resolution; n, number of patients who completed week 24 and had EC available at both baseline and week 24

Back to article page